^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Selzentry (maraviroc)

    i
    Other names: UK-427857, MVC, UK 427857, UK427857
    Company:
    ViiV Healthcare
    Drug class:
    CCR5 receptor antagonist
    Related drugs:
    Apply
    Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (NCT05470491)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    01/26/2023
    Primary completion :
    07/30/2026
    Completion :
    07/30/2027
    IGH
    |
    bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor
    Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC (PICCASSO) (NCT03274804)
    Phase 1
    University Hospital Heidelberg
    Completed
    Last update posted :
    06/07/2022
    Initiation :
    04/01/2018
    Primary completion :
    03/01/2020
    Completion :
    03/01/2020
    BRAF
    |
    BRAF wild-type
    |
    Keytruda (pembrolizumab) • Selzentry (maraviroc)
    Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) (NCT01276236)
    Phase 2
    University of California, San Francisco
    Completed
    Last update posted :
    03/05/2021
    Initiation :
    03/09/2011
    Primary completion :
    01/31/2015
    Completion :
    04/30/2015
    CD8 • CD38 • CD4 • CD69
    |
    CD38 positive • CD8 negative
    |
    Selzentry (maraviroc)
    Phase II Maraviroc for GVHD Prevention (NCT01785810)
    Phase 2
    Abramson Cancer Center of the University of Pen...
    Completed
    Last update posted :
    01/11/2021
    Initiation :
    02/01/2013
    Primary completion :
    11/11/2016
    Completion :
    07/12/2018
    HLA-DRB1 • HLA-B • HLA-C
    |
    Selzentry (maraviroc)
    Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (NCT02208037)
    Phase 2
    National Heart, Lung, and Blood Institute (NHLBI)
    Completed
    Last update posted :
    01/23/2019
    Initiation :
    08/01/2014
    Primary completion :
    10/01/2017
    Completion :
    10/01/2017
    HLA-DRB1 • HLA-B • HLA-C
    |
    bortezomib • cyclophosphamide • Selzentry (maraviroc) • cyclophosphamide intravenous